Melissa B. Epperly - 01 Oct 2026 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Reporting relationship: Director
Issuer ticker: ROIV
Reported as of: 01 Oct 2026
Net transaction value: -$640,861
SEC form: 4
Accepted by SEC: 05 Oct 2026, 18:05:55 UTC
Prior SEC filing: 18 Sep 2026
Source filing: View source filing
Reporting owner signature: By: /s/ Sam Kaplan, as Attorney-in-Fact for Melissa Epperly

Key filing fact

Melissa B. Epperly filed Form 4 for Roivant Sciences Ltd. (ROIV) on 05 Oct 2026.

Key facts

This page summarizes Melissa B. Epperly's Form 4 filing for Roivant Sciences Ltd. (ROIV).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Oct 2026, 18:05.

Change

Previous filing in this sequence was filed on 18 Sep 2026.
Current net transaction value: -$640,861.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001807359 Primary reporting owner

Epperly Melissa B,

Relationship: Director
Address: C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM
Signature: By: /s/ Sam Kaplan, as Attorney-in-Fact for Melissa Epperly
Signature date: 05 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ROIV transaction

Common Shares

Options Exercise

Transaction value
Shares: +17,750
Change %: +119%
Price: $4.46^*
Shares after: 32,704
Date: 01 Oct 2026
Ownership: Direct

ROIV transaction

Common Shares

Sale

Transaction value: $607,948
Shares: -16,850
Change %: -52%
Price: $36.08
Shares after: 15,854
Date: 01 Oct 2026
Ownership: Direct
Footnotes: F1

ROIV transaction

Common Shares

Sale

Transaction value: $32,913
Shares: -900
Change %: -5.7%
Price: $36.57
Shares after: 14,954
Date: 01 Oct 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ROIV transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -17,750
Change %: -10%
Price: $0.000000^*
Shares after: 151,416
Date: 01 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,750
Exercise price: $4.46
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.46 to $36.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.

Footnote F2

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.48 to $36.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.

Footnote F3

Reflects an award of stock options to purchase Common Shares that is fully vested.